index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
1,early growth response protein 1,protein,,egr1,uniprot,q92579,nucleus,go:0005634,pten,protein,,pten,uniprot,q00533,plasma membrane,go:0005886,positive,d,binds,pten promoter region,,,,human,['29'],nan,nan,"in addition to gene mutations, complete or partial loss of pten protein expression may impact pten's tumor suppression ability. the regulation of pten's functions and signaling pathway is shown in figure 2. positive regulators of pten gene expression include early growth response protein 1, peroxisome proliferator-activated receptor γ (pparγ) and p53, which have been shown to directly bind to the pten promoter region [27–29]. early growth response protein 1, which regulates pten expression during the initial steps of apoptosis, has been shown to directly upregulate the expression of pten in non–small cell lung cancer. pparγ is a ligand-activated transcription factor with anti-inflammatory and anti-tumor effects. the activation of its selective ligand, rosiglitazone, leads to the binding of pparγ at two pten promoter sites, ppar response element 1 and ppar response element 2, thus upregulating pten and inhibiting pi3k activity. negative regulators of pten gene expression include mitogen-activated protein kinase kinase-4, transforming growth factor beta (tgf-β), nuclear factor of kappa light polypeptide gene enhancer in b-cells (nf-κb), igf-1, the transcriptional cofactor c-jun proto-oncogene, and the b-cell-specific moloney murine leukemia virus insertion site 1 (bmi1) proto-oncogene, which have been shown to suppress pten expression in several cancer models [30–32]. research found that igf-1 could affect cell proliferation and invasion by suppressing pten's phosphorylation. in pancreatic cancers, tgf-β significantly suppresses pten protein levels concomitant with the activation of akt through transcriptional reduction of pten mrna–induced growth promotion. c-jun negatively regulates the expression of pten by binding to the activator protein 1 site of the pten promoter, resulting in the concomitant activation of the akt pathway. pten transcription is also directly repressed by the leukemia-associated factor ecotropic virus integration site 1 protein in the hematopoietic system [33].",pmc4712330,1,100,40,1,140
2,itk,protein,,itk,uniprot,q05232,plasma membrane,go:0005886,foxp3,protein,,fosl1,uniprot,p61479,plasma membrane,go:0005886,positive,d,phosphorylation,,,naive,,mouse,['2'],nan,nan,"to determine whether the increased differentiation into foxp3+-expressing cells was a more global property of itk−/− cd4+ t cells, we evaluated the differentiation of naive cells under treg cell conditions. when naive cd4+ cells were stimulated with standard concentrations of anti-cd3 (1 µg/ml) in the presence of wt apcs plus il-2 and tgf-β1, a significantly higher percentage of itk-deficient cells became foxp3+ than cells from wt mice (65.4 ± 2.9% vs. 40.1 ± 1.6% in wt cells; fig. 2 a). accordingly, naive itk−/− cd4+ t cells differentiated under these itreg cell–inducing conditions exhibited higher amounts of foxp3 mrna than wt itreg cells (fig. 2 b). similar observations were obtained when naive cd4+ t cells from 5cc7 transgenic mice were differentiated in the presence of treg cell–inducing cytokines (fig. 2 c). naive gfp−cd4+ t cells sorted from itk−/− foxp3gfp mice also gave rise to higher percentages of foxp3+ itreg cells compared with wt mice (fig. 2 d), arguing that these observations were not the result of outgrowth of foxp3+ cells present before culturing. thus, naive cd4+ t cells deficient in itk give rise to increased foxp3+ cells in vitro.",pmc3949578,1,100,40,1,140
4,pi3k,enzyme,,pi3k,uniprot,p00055,plasma membrane,go:0005886,akt,protein,,akt1,uniprot,q05209,plasma membrane,go:0005886,positive,d,phosphorylation,,,,,human,['25'],nan,nan,"only pi3k pan-inhibition switched off akt signaling, as demonstrated by the reduction or complete abrogation of both thr308 and ser473 p-akt levels. it has been previously reported that a limited pi3k activity is sufficient to support cell survival and proliferation and, consequently, complete pi3k inhibition is required to induce cell death [48]. consistent with that, in spite of changes in cell cycle progression, we observed a significant cell death induction almost exclusively after pi3k pan-inhibition, with the exception of loucy cells where the dual inhibition of p110γ/δ was also effective. importantly, we demonstrated that, at least in the case of zstk-474, the mechanisms involved in cell death are independent of caspase activity as a pan-caspase inhibitor did not reduce cell death.",pmc4496363,1,100,40,1,140
5,pten,protein,,pten,uniprot,q96630,plasma membrane,go:0005886,pdk1,protein,,pdk1,uniprot,q96631,plasma membrane,go:0005886,negative,d,inhibits,,,b-cell,,mouse,['26'],nan,nan,"a recent study in which ptenfl/fl × cd4-cre mice were crossed to pdk1fl/fl mice has shown that while lymphoma did not develop in this model of t cell-specific pten deletion, pdk1/akt signaling was dispensable for the survival, proliferation and differentiation of t cell progenitors, and in vivo expansion of peripheral t cells (finlay et al., 2009). the mechanism for control of cell metabolism independent of pdk1 is unclear in these mice, although thymocyte proliferation in the absence of pten was shown to require rhoa-dependent pathways, and a dependence on c-myc, which was recently shown to play a pivotal role in t cell metabolism following activation (wang et al., 2011), was not ruled out. mice which express a single hypomorphic pdk1 allele similarly prevented a wide range of tumors when crossed to pten heterozygous mice, indicating that the requirement for pdk1 in the context of tumor formation brought on by loss of pten is not limited to its role in controlling migratory capacity of t cells (bayascas et al., 2005). additionally, deletion of s6k1 in the mx-1-cre model of pten loss resulted in delayed development of leukemia, indicating that an mtorc1-mediated pathway, in this context shown to involve induction of a hif-1α-dependent glycolytic program, contributes to leukemogenesis in pten-deficient cells (tandon et al., 2011).",pmc3375464,1,10,38,1,48
0,bcl-xl,protein,,bcl2l1,uniprot,q07817,mitochondria,go:0005739,apaf-1,protein,,apaf1,uniprot,o14727,mitochondria,go:0005739,negative,d,binds,,hek 293t,epithelial-like,kidney,human,['28'],nan,nan,"pten's tumor suppressor function is usually abrogated following mutations in its phosphatase domain, which is encoded by exon 5 [23] (figure 1). these mutations typically include a c124s mutation that abrogates both lipid and protein phosphatase activity and a g129e mutation that abrogates lipid phosphatase but not protein phosphatase activity [24]. although the n-terminal phosphatase domain is principally responsible for pten's physiological activity, approximately 40% of tumorigenic pten mutations occur in the c-terminal c2 domain (corresponding to exons 6, 7, and 8) and in the tail sequence (corresponding to exon 9), which encode for tyrosine kinase phosphorylation sites. this suggests that the c-terminal sequence is critical for maintaining pten function and protein stability [21, 23, 25, 26]. however, many tumor-derived pten mutants retain partial or complete catalytic function, suggesting that alterative mechanisms can lead to pten inactivation.",pmc4712330,1,0.1,39,1,39.1
3,pd-l1,protein,,pdcd1l1,uniprot,q07817,plasma membrane,go:0005886,cd8-,protein,,cd8a,uniprot,p01730,plasma membrane,go:0005886,positive,d,binds,,,t-cell,,human,['53'],nan,nan,"impact of pd-l1 blockade for treg, cd4- and cd8- t cells.",pmc4669187,1,0.1,39,1,39.1
6,tbk1,protein,,tbk1,uniprot,q9hzs6,cytosol,go:0005731,carma1,protein,,carma1,uniprot,q9y2a7,cytosol,go:0005731,negative,d,binds,,b6,t-cell,,mouse,['11'],nan,nan,"the tbk1-flox mice were generated in b6 × 129 mixed genetic backgrounds44 and further backcrossed to the b6 mice for four generations. to generate t-cell-conditional tbk1-ko mice, tbk1-flox mice44 were crossed with cd4-cre transgenic mice (b6 genetic background, jackson laboratories), producing tbk1+/+cd4-cre (named wt) and tbk1fl/flcd4-cre (named tbk1-tko mice) mice. tbk1-flox mice were also crossed with rosa26-cre-er mice (b6 genetic background, jackson laboratories) and the progeny tbk1+/+rosa26-cre-er and tbk1fl/flrosa26-cre-er mice were injected i.p. with tamoxifen (2 mg per mouse) in corn oil daily for four consecutive days to induce cre function. the tamoxifen-treated tbk1+/+rosa26-cre-er and tbk1fl/flrosa26-cre-er mice were named wt-er and tbk1-er mice, respectively, and used 2 weeks after the treatment. carma1-ko mice (b6 × 129 genetic background) were provided by dr josef m. penninger (austrian academy of sciences)46. mice with loxp-flanked allele encoding ikkβ (ikk2) or nemo alleles were provided by dr manolis pasparakis (university of cologne)47. these mice were crossed with cd4-cre mice to generate the t-cell-conditional ikkβ ko (ikkβ-tko) and nemo ko (nemo-tko) mice. ikkε-ko, b6.sjl (cd45.1+), c57bl/6, rag1-ko and tcrβ/δ ko mice were from jackson laboratory. experiments were performed with age-matched mice. mice were maintained in a specific pathogen-free facility of the university of texas md anderson cancer center, and all animal experiments were done in accordance with protocols approved by the institutional animal care and use committee of the university of texas md anderson cancer center.",pmc4302769,1,0.1,39,1,39.1
